Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Interventional Observational Study Evaluating The Effects Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy On Safety In Postmenopausal And Hormone Receptors Positive Early Breast Cancer Patients

NCT01155063 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01155063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01155063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Interventional Observational Study Evaluating The Effects Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy On Safety In Postmenopausal And Hormone Receptors Positive Early Breast Cancer Patients
Lead sponsor
Pfizer
Phase
Observational
Overall status
Terminated
Start date
September 30, 2010
Completion date
September 30, 2011
Enrollment
89 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

early breast cancer